Omnicell: Buying the Q2 Print as Automation Momentum Outweighs Bookings Noise
Omnicell (OMCL) is a mid-cap healthcare automation play with a $1.9B market cap, steady free cash flow and a clear product roadmap. Recent booking softness is a near-term headwind, but attractive EV/sales (~1.5), positive FCF ($119M), and continued adoption of pharmacy automation make a case to buy ahead of Q2 results. I propose a defined long with…